-
1.
公开(公告)号:US20160200718A1
公开(公告)日:2016-07-14
申请号:US14956767
申请日:2015-12-02
Applicant: ALMIRALL, S.A.
Inventor: Jose AIGUADE BOSCH , Silvia GUAL ROIG , Maria PRAT QUINONES , Carlos PUIG DURAN
IPC: C07D417/14 , A61K31/4709 , A61K45/06 , A61K31/538 , C07D409/12 , A61K31/4184 , A61K31/423 , C07D413/14 , C07D409/14
CPC classification number: A61K31/538 , A61K31/4178 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/4709 , A61K45/06 , C07D263/58 , C07D401/12 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
-
公开(公告)号:US20150246026A1
公开(公告)日:2015-09-03
申请号:US14712866
申请日:2015-05-14
Applicant: ALMIRALL, S.A.
IPC: A61K31/439 , A61K9/00 , A61K31/56 , A61K47/26 , A61K45/06
CPC classification number: A61K31/439 , A61K9/0073 , A61K9/0075 , A61K31/4745 , A61K31/56 , A61K45/06 , A61K47/26 , C07D453/02 , Y10S514/826 , A61K2300/00
Abstract: A compound according to formula (I) wherein z© is a phenyl ring, a C4 to C9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; R1, R2 and R3 each independently represent a hydrogen or halogen atom, or a hydroxy group, or a phenyl, —OR4, —SR4, —NR4R5, —NHCOR4, —CONR4R5, —CN, —NO2, —COOR4 or —CF3 group, or a straight or branched lower alkyl group which may optionally be substituted, for example, with a hydroxy or alcoxy group, wherein R4 and R5 each independently represent a hydrogen atom, straight or branched lower alkyl group, or together form an alicyclic ring; or R1 and R2 together form an aromatic, alicyclic or heterocyclic ring; n is an integer from 0 to 4; A represents a —CH2—, —CH═CR6, —CR6═CH—, —CR6122—, —CO—, —O—, —S—, —S(O)—, SO2 or NR6— group, wherein R6 and R2 each independently represent a hydrogen atom, straight or branched lower alkyl group, or R6 and 122 together form an alicyclic ring; m is an integer from 0 to 8; provided that when m=0, A is not —CH2—; p is an integer from 1 to 2 and the substitution in the azoniabicyclic ring may be in the 2,3 or 4 position including all possible configurations of the asymmetric carbons; B represents a group of formula (i) or (ii), wherein R10 represents a hydrogen atom, a hydroxy or methyl group; and R8 and R9 each independently represents formulae (a), (b), (c), (d) and wherein R11 represents a hydrogen or halogen atom, or a straight or branched lower alkyl group and Q represents a single bond, —CH2—, —CH2—CH2, —O—, —O—CH2—, —S—, —S—CH2— or —CH═CH—, and when (i) or (ii) contain a chiral centre they may represent either configuration; X represents a pharmaceutically acceptable anion of a mono or polyvalent acid, which shows high affinity for muscarinic M3 receptors (Hm3).
-
公开(公告)号:US20170319557A1
公开(公告)日:2017-11-09
申请号:US15599646
申请日:2017-05-19
Applicant: ALMIRALL, S.A.
IPC: A61K31/439 , C07D453/02 , A61K9/00 , A61K31/56 , A61K31/4745 , A61K45/06 , A61K47/26
CPC classification number: A61K31/439 , A61K9/0073 , A61K9/0075 , A61K31/4745 , A61K31/56 , A61K45/06 , A61K47/26 , C07D453/02 , Y10S514/826 , A61K2300/00
Abstract: Provided is a powder inhaler comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X− is associated with the positive charge of the nitrogen atom and wherein X− is a pharmaceutically acceptable anion of a mono- or polyvalent acid
-
公开(公告)号:US20140303126A1
公开(公告)日:2014-10-09
申请号:US14311102
申请日:2014-06-20
Applicant: ALMIRALL, S.A.
IPC: C07D453/02 , A61K45/06 , A61K31/439
CPC classification number: A61K31/439 , A61K9/0073 , A61K9/0075 , A61K31/4745 , A61K31/56 , A61K45/06 , A61K47/26 , C07D453/02 , Y10S514/826 , A61K2300/00
Abstract: A compound according to formula (I) wherein z© is a phenyl ring, a C4 to C9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; R1, R2 and R3 each independently represent a hydrogen or halogen atom, or a hydroxy group, or a phenyl, —OR4, —SR4, —NR4R5, —NHCOR4, —CONR4R5, —CN, —NO2, —COOR4 or —CF3 group, or a straight or branched lower alkyl group which may optionally be substituted, for example, with a hydroxy or alcoxy group, wherein R4 and R5 each independently represent a hydrogen atom, straight or branched lower alkyl group, or together form an alicyclic ring; or R1 and R2 together form an aromatic, alicyclic or heterocyclic ring; n is an integer from 0 to 4; A represents a —CH2—, —CH═CR6, —CR6═CH—, —CR6R7—, —CO—, —O—, —S—, —S(O)—, SO2 or NR6— group, wherein R6 and R7 each independently represent a hydrogen atom, straight or branched lower alkyl group, or R6 and R7 together form an alicyclic ring; in is an integer from 0 to 8; provided that when m=0, A is not —CH2—; p is an integer from 1 to 2 and the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; B represents a group of formula (i) or (ii), wherein R10 represents a hydrogen atom, a hydroxy or methyl group; and R8 and R9 each independently represents formulae (a), (b), (c), (d) and wherein R11 represents a hydrogen or halogen atom, or a straight or branched lower alkyl group and Q represents a single bond, —CH2—, —CH2—CH2, —O—, —O—CH2—, —S—, —S—CH2— or —CH═CH—, and when (i) or (ii) contain a chiral centre they may represent either configuration; X represents a pharmaceutically acceptable anion of a mono or polyvalent acid, which shows high affinity for muscarinic M3 receptors (Hm3).
-
5.NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME 有权
Title translation: 新颖的喹啉衍生物和含有它们的药物组合物公开(公告)号:US20160296503A1
公开(公告)日:2016-10-13
申请号:US15095036
申请日:2016-04-09
Applicant: ALMIRALL, S.A.
IPC: A61K31/439 , A61K45/06 , A61K31/56 , A61K9/00 , A61K47/26
CPC classification number: A61K31/439 , A61K9/0073 , A61K9/0075 , A61K31/4745 , A61K31/56 , A61K45/06 , A61K47/26 , C07D453/02 , Y10S514/826 , A61K2300/00
Abstract: Provided is an aerosol container comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X− is associated with the positive charge of the nitrogen atom and wherein X− is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
Abstract translation: 本发明提供一种气溶胶容器,其包含粉末吸入剂,其包含3(R) - (2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓二环[2.2.2]辛烷,其中 阴离子X-与氮原子的正电荷相关,其中X-是单价或多价酸的药学上可接受的阴离子。
-
6.NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES 有权
Title translation: 具有β2ADRENERGIC AGONIST和M3 MUSCARINIC ANTAGONIST活动的新CYCLOHEXYLAMINE衍生物公开(公告)号:US20160264557A1
公开(公告)日:2016-09-15
申请号:US15068926
申请日:2016-03-14
Applicant: Almirall, S.A.
Inventor: Maria PRAT QUINONES , Silvia FONQUERNA POU , Carlos PUIG DURAN , Wenceslao LUMERAS AMADOR , Jose AIGUADE BOSCH , Juan Francisco CATURLA JAVALOYES
IPC: C07D409/14 , C07D409/12 , C07D215/26 , C07D413/14 , C07D405/12
CPC classification number: C07D409/14 , A61K31/4709 , C07D215/26 , C07D405/12 , C07D409/12 , C07D413/14
Abstract: The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
Abstract translation: 本发明涉及具有β2肾上腺素能激动剂和M3毒蕈碱拮抗剂双重活性的新化合物,含有它们的药物组合物,其制备方法及其在呼吸治疗中的用途。
-
公开(公告)号:US20190183867A1
公开(公告)日:2019-06-20
申请号:US16045333
申请日:2018-07-25
Applicant: ALMIRALL, S.A.
IPC: A61K31/439 , A61K9/00 , A61K47/26 , A61K31/4745 , C07D453/02 , A61K45/06 , A61K31/56
Abstract: Provided is a method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropy1)-1-azoniabicyclo[2.2.2]octane bromide.
-
8.NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES 有权
Title translation: 具有β2ADRENERGIC AGONIST和M3 MUSCARINIC ANTAGONIST活动的新CYCLOHEXYLAMINE衍生物公开(公告)号:US20160143915A1
公开(公告)日:2016-05-26
申请号:US14956836
申请日:2015-12-02
Applicant: ALMIRALL, S.A.
Inventor: Jose AIGUADE BOSCH , Silvia GUAL ROIG , Maria PRAT QUINONES , Carlos PUIG DURAN
IPC: A61K31/538 , A61K31/428 , A61K31/423 , A61K31/4709 , A61K31/4184
CPC classification number: A61K31/538 , A61K31/4178 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/4709 , A61K45/06 , C07D263/58 , C07D401/12 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
Abstract translation: 本发明涉及具有β-肾上腺素能激动剂和M3毒蕈碱拮抗剂双重活性的新化合物,含有它们的药物组合物,其制备方法及其在呼吸治疗中的用途。
-
-
-
-
-
-
-